Brickell Biotech Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Brickell Biotech Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10592
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Brickell Biotech Inc (Brickell Biotech) is a pharmaceutical company that develops differentiated therapeutics for the treatment of skin diseases. The company offers pipeline product candidates such as BBI-4000, BBI-5000, BBI-2000, BBI-3000 and BBI -6000. Its product candidate BBI-4000 is an anticholinergic used for the treatment of primary axillary hyperhidrosis; BBI-5000, a selective oral immunomodulator for moderate to severe atopic dermatitis. Brickell Biotech’s BBI-2000, is an anti-inflammatory peptide in pre-clinical stage for contact dermatitis, and BBI-3000, a potent topical and oral retinoid in pre-clinical stage for the treatment of acne. The company serves cosmetic and aesthetics companies, pharmaceutical and healthcare companies. Brickell Biotech is headquartered in Boulder, Colorado, the US.

Brickell Biotech Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Brickell Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Brickell Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Brickell Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Brickell Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Brickell Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Brickell Biotech Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Brickell Biotech Acquires Rights to RORy Inhibitors from Orca Pharma 10
Venture Financing 11
Brickell Biotech Raises USD10 Million in Series C Financing 11
Brickell Biotech Raises USD2.2 Million in Venture Financing 12
Brickell Biotech Raises US$7 Million In Series B Financing 13
Licensing Agreements 14
Brickell Biotech Enters into Licensing Agreement with Kaken Pharma 14
Brickell Biotech Enters into Licensing Agreement with Merz North America for BBI-3000 15
Brickell Biotech Enters into Licensing Agreement with Bodor Labs 16
Argyle Therapeutics Enters Into Licensing Agreement With Brickell Biotech For Rosacea Drug 17
Brickell Biotech Inc – Key Competitors 18
Brickell Biotech Inc – Key Employees 19
Brickell Biotech Inc – Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Brickell Biotech Inc, Pharmaceuticals & Healthcare, Key Facts 2
Brickell Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Brickell Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Brickell Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Brickell Biotech Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Brickell Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Brickell Biotech Acquires Rights to RORy Inhibitors from Orca Pharma 10
Brickell Biotech Raises USD10 Million in Series C Financing 11
Brickell Biotech Raises USD2.2 Million in Venture Financing 12
Brickell Biotech Raises US$7 Million In Series B Financing 13
Brickell Biotech Enters into Licensing Agreement with Kaken Pharma 14
Brickell Biotech Enters into Licensing Agreement with Merz North America for BBI-3000 15
Brickell Biotech Enters into Licensing Agreement with Bodor Labs 16
Argyle Therapeutics Enters Into Licensing Agreement With Brickell Biotech For Rosacea Drug 17
Brickell Biotech Inc, Key Competitors 18
Brickell Biotech Inc, Key Employees 19

List of Figures
Brickell Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Brickell Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Brickell Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Brickell Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Brickell Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Brickell Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Brickell Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Brickell Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Brickell Biotech Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Eni S.p.A:企業の戦略・SWOT・財務情報
    Eni S.p.A - Strategy, SWOT and Corporate Finance Report Summary Eni S.p.A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Peak Resources Ltd. (PEK):企業の財務・戦略的SWOT分析
    Peak Resources Ltd. (PEK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Praxair Inc (PX)-石油・ガス分野:企業M&A・提携分析
    Summary Praxair Inc (Praxair) is a producer and supplier of industrial gases. The company offers atmospheric gases including oxygen, nitrogen, argon and rare gases, and process gases such as carbon dioxide, helium, hydrogen, electronic gases, specialty gases and acetylene. It also designs and builds …
  • Seafarms Group Limited (SFG):企業の財務・戦略的SWOT分析
    Seafarms Group Limited (SFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Cathay Pacific Airways Limited
    Cathay Pacific Airways Limited - Strategy, SWOT and Corporate Finance Report Summary Cathay Pacific Airways Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • BASF Corp:企業のM&A・事業提携・投資動向
    BASF Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BASF Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Whole Foods Market Inc:企業のM&A・事業提携・投資動向
    Whole Foods Market Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Whole Foods Market Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Continental Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Continental Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Continental Resources Inc (Continental Resources) is an oil and gas company involved in the distribution of fuel and related products and services. The company offerings include supply fulf …
  • TIBCO Software, Inc.:企業の戦略・SWOT・財務情報
    TIBCO Software, Inc. - Strategy, SWOT and Corporate Finance Report Summary TIBCO Software, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • LIC of India:企業の戦略・SWOT・財務分析
    LIC of India - Strategy, SWOT and Corporate Finance Report Summary LIC of India - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Elasmogen Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Elasmogen Ltd (Elasmogen), formerly Pacific Shelf 1760 Ltd, is a biopharmaceutical company which focuses on the development of soloMER products for the treatment of auto-inflammatory diseases, ophthalmology, oncology and intracellular delivery. soloMERs are proprietary humanized clinical can …
  • OncoSec Medical Inc (ONCS)-医療機器分野:企業M&A・提携分析
    Summary OncoSec Medical Inc (OncoSec) is a biotechnology company that offers services to stimulate body’s immune system and attack cancer. It’s lead candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through i …
  • Leidos Biomedical Research Inc-製薬・医療分野:企業M&A・提携分析
    Summary Leidos Biomedical Research Inc (Leidos), formerly SAIC-Frederick Inc, a subsidiary of Leidos Holdings Inc is a biomedical research center that develops therapies. The center offers operations and technical support services. It provides research and maintenance programs in areas of genetics, …
  • Merge Healthcare Inc:医療機器:M&Aディール及び事業提携情報
    Summary Merge Healthcare Inc (Merge Technologies), a subsidiary of International Business Machines Corp, is a medical technology company that offers advanced solutions specifically designed for healthcare. The company's solutions include cardiology, orthopedics, interoperability, radiology, eye care …
  • Monsanto Company:企業の戦略・SWOT・財務分析
    Monsanto Company - Strategy, SWOT and Corporate Finance Report Summary Monsanto Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Zion Oil & Gas Inc (ZN):企業の財務・戦略的SWOT分析
    Summary Zion Oil & Gas Inc (Zion Oil) is an oil and gas company that explores and produces oil and gas properties in Israel. The company offers services such as geophysical, geological, and other science-based studies and surveys to support oil and gas exploration and development services. It holds …
  • GI Dynamics Inc (GID):企業の財務・戦略的SWOT分析
    Summary GI Dynamics Inc (GI Dynamics) is a clinical stage medical device company that develops and commercializes endoscopy instruments. The company develops EndoBarrier, a device to treat type 2 diabetes and obesity, which is delivered endoscopically. The device imitates the mechanisms of metabolic …
  • Mitie Group Plc (MTO):企業の財務・戦略的SWOT分析
    Mitie Group Plc (MTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Caldera Health Ltd:製品パイプライン分析
    Summary Caldera Health Ltd (Caldera) is a medical device company that develops prostate cancer diagnostic tools. The company develops prostate cancer diagnostic tools to detect and monitor the cancer disease. It also develops proscanZ and auditor tests based on the enzyme linked immunoassays or ELIS …
  • Bloomsbury Publishing Plc (BMY):企業の財務・戦略的SWOT分析
    Bloomsbury Publishing Plc (BMY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆